GlassScriptPhysician profile
Scarlette D Smith
NPI 1386636132
$6,337.06
in general payments reported to CMS, 2019-2025
29 companies · $60.00 in 2025
The $60.00 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $897 · 2021: $1,326 · 2022: $2,131 · 2023: $1,020 · 2024: $251 · 2025: $60.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.15 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,407.52 | 2019-2023 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,067.98 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $429.09 | 2022-2023 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $385.03 | 2019-2023 | Ilumya |
| Leo Pharma INC. | $341.59 | 2020-2023 | Adbry |
| Ucb, INC. | $309.35 | 2020-2023 | Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $291.09 | 2019-2023 | Jublia, Arazlo, Duobrii |
| Lilly USA, LLC | $235.94 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $215.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $210.62 | 2019-2022 | |
| Pfizer INC. | $207.28 | 2019-2023 | |
| Incyte Corporation | $183.16 | 2022-2025 | Opzelura |
| Prugen, INC. Pharmaceuticals | $159.60 | 2019 | |
| Mayne Pharma Commercial LLC | $140.68 | 2020-2023 | |
| Vyne Pharmaceuticals INC. | $130.25 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $95.16 | 2021 | |
| Genzyme Corporation | $84.40 | 2021-2022 | |
| Dermira, INC. | $64.18 | 2020 | |
| Galderma Laboratories, L.P. | $61.72 | 2020-2023 | Aklief |
| Dermavant Sciences, INC. | $60.37 | 2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $45.50 | 2019 | |
| Epi Health, LLC | $43.37 | 2020-2022 | |
| Aclaris Therapeutics, INC. | $32.56 | 2019 | |
| Biofrontera INC. | $32.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $27.69 | 2024 | Saphnelo |
| Genentech USA, INC. | $23.46 | 2022 | |
| Nabriva Therapeutics, Plc | $22.24 | 2022 | |
| Allergan, INC. | $15.00 | 2021 | |
| Almirall LLC | $14.87 | 2023 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scarlette Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.